The new Sanofi won’t look much like the old one
The Sanofi of today, a $57 billion enterprise, exists in large part because of the heart drug Plavix and the long-acting insulin Lantus. The Sanofi of tomorrow won’t spend a dollar trying to replicate them.
The company said yesterday that it’s abandoning research in diabetes and cardiovascular disease, planning to finish studies on a major diabetes medicine it is developing without plans to bring it to market. After that, the company’s focus will be oncology, hematology, rare disease, neurology, and growing its presence in China.
The pivot marks the first big strategic move by CEO Paul Hudson, who took the reins in September.
Read more.
The company said yesterday that it’s abandoning research in diabetes and cardiovascular disease, planning to finish studies on a major diabetes medicine it is developing without plans to bring it to market. After that, the company’s focus will be oncology, hematology, rare disease, neurology, and growing its presence in China.
The pivot marks the first big strategic move by CEO Paul Hudson, who took the reins in September.
Read more.
No hay comentarios:
Publicar un comentario